Target, Home Depot,...
Health Care: Drugs
iBio Inc. (IBIO: AMEX)
$0.41 0.01 | 2.50%
05/17/13 - 03:59 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.41 |
| 52 Week High | 1.70 |
| 52 Week Low | 0.38 |
| Avg. Daily Vol. (Mil) | 0.11 |
| Beta (3 year) | 1.08 |
| Share Related Items | |
| Mkt Cap (Mil) | 19.58 |
| Shares Out (Mil) | 47.77 |
| Float (Mil) | 36.26 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.00 |
| Current Ratio | 1.30 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 17.59 |
| Price/Book | 5.27 |
| Price/Cash Flow | -2.70 |
| Per Share Data | |
| Earnings | -0.15 |
| Sales | 0.02 |
| Book Value | 0.08 |
| Cash Flow | -0.15 |
| Business Summary | |
|---|---|
| iBio Inc is a biotechnology company, focused on developing vaccines and therapeutic proteins based upon its proprietary plant-based iBioLaunch Platform Technology. | |
| General Information | |
| 9 Innovation Way
Suite 100 Newark, DE 19711 |
|
| www.ibioinc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 7 | |
| CEO: Mr. Robert B. Kay | |
| Short Interest | |
| Current Month (Mil) | 0.63 |
| Previous Month (Mil) | 0.58 |
| Short Interest Ratio (Days) | 4.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -111.40 |
| Return on Investments | -204.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with IBIO
- Portfolio NameUser Type
- Usercosmo
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
Latest IBIO Headlines from TheStreet
- 4 Biotech Stocks Under $10 Moving Higher 10.05.12 | 08:10 am
- 5 Stocks Under $10 Setting Up to Break Out 09.13.12 | 12:09 pm
- 10 New Stocks Rated by TheStreet 08.03.11 | 02:08 pm
Press Releases for IBIO
- GE Alliance Awarded Contract To Design New Plant-based Manufacturing Facility In Brazil - PR Newswire 04.09.13 | 07:04 am
- IBio Selects Proprietary Recombinant C1 Inhibitor For Clinical Development - PR Newswire 03.26.13 | 07:03 am
- IBio Adds To IBioModulator Portfolio And Product Pipeline - PR Newswire 03.13.13 | 07:03 am
- IBio Adds New Therapeutic Antibody To Its Pipeline - PR Newswire 03.04.13 | 09:03 am
- IBio, Inc. Receives Anticipated Notice From NYSE MKT That Company Is Below Certain Continued Listing Standards - PR Newswire 03.04.13 | 09:03 am
- IBio And Caliber Biotherapeutics Establish License And Collaboration Relationship - PR Newswire 02.19.13 | 07:02 am
- IBio, Inc. Receives Approval From NYSE MKT Of Compliance Plan - PR Newswire 02.13.13 | 07:02 am
- IBio Announces At-the-Market Equity Offering - PR Newswire 02.01.13 | 09:02 am
- IBio Announces New Appointment To Board Of Directors And New Addition To Executive Management Team - PR Newswire 12.21.12 | 07:12 am
- National Institute Of Health Awards Contract To Support Use Of IBio's Proprietary Technology For Improved Anthrax Vaccine - PR Newswire 12.05.12 | 07:12 am
Partner Headlines for IBIO
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- Rituxan And Its Biosimilar Competitors - Seeking Alpha 07.30.12 | 09:07 am
- iBio Announces Proposed Public Offering; No Amount Given - Benzinga 01.09.12 | 04:01 pm
- IBIO: Pharma Stock With Much Downside Risk And Low Upside Potential - Seeking Alpha 11.02.11 | 08:11 am
- iBio Still Overvalued; More Dilution Likely - Seeking Alpha 06.29.11 | 09:06 am
- Trading Resumes: iBio, Inc. - Benzinga 03.08.11 | 01:03 pm
- iBio Overvalued - Seeking Alpha 02.09.11 | 08:02 am
- 4 Stocks for the Aggressive Investor - Seeking Alpha 02.02.11 | 08:02 am
- iBio: A True Paradigm Shift - Seeking Alpha 01.24.11 | 09:01 am
